Autologous Anti-CD22 CAR-expressing T-cells SCRI-CAR22v2

Preferred Label : Autologous Anti-CD22 CAR-expressing T-cells SCRI-CAR22v2;

NCIt synonyms : Autologous CD22-CAR-expressing T Lymphocytes SCRI-CAR22v2; Autologous Anti-CD22 CAR-T Cells SCRI-CAR22v2;

NCIt definition : A preparation of autologous human T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD22 CAR-expressing T-cells SCRI-CAR22v2 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces leading to lysis of CD22-expressing B-cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.;

Molecule name : SCRI-CAR22v2; SCRI CAR22v2;

NCI Metathesaurus CUI : CL1642402;

Details

Origin ID

C176568;

UMLS CUI

C5448063;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Cell Receptor CD22 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients